Ergomed’s partner Aeterna Zentaris signs agreement with Sinopharm A-Think for zoptarelin doxorubicin in China

Ergomed plc, a profitable UK-based company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, has announced that Aeterna Zentaris has signed an exclusive licence and technology transfer agreement with Sinopharm A-Think for the Chinese, Hong Kong and Macau markets for zoptarelin doxorubicin which is in Phase 3 development for treating endometrial cancer.  Sinopharm A-Think will be responsible for the development, production, registration and commercialization of the product in these markets.

As previously announced, Ergomed signed a Co-Development and Profit Sharing Agreement with Aeterna Zentaris in 2013 and is working with Aeterna Zentaris  on the Phase 3 ZoptEC (Zoptarelin doxorubicin in Endometrial Cancer) pivotal trial comparing zoptarelin doxorubicin with doxorubicin as second line therapy for locally-advanced, recurrent or metastatic endometrial cancer.

Miroslav Reljanovic, Chief Executive Officer of Ergomed, commented:  “Our collaboration with Aeterna Zentaris on zoptarelin doxorubicin is progressing very well through its pivotal Phase III trial. We are pleased that Aeterna Zentaris has signed this collaboration with Sinopharm, the largest pharmaceutical company in China, which is a validation of the potential for this compound. We believe our co-development model has the potential to generate significant value for Ergomed and its shareholders.”